Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial

Mordchai Ravid*, David Brosh, Zohar Levi, Yosefa Bar-Dayan, Dorit Ravid, Rita Rachmani

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Angiotensin-converting enzyme (ACE) inhibitors attenuate the decline in renal function in diabetic patients with microalbuminuria. However, no data are available on the use of ACE inhibitors to prevent the decrease in renal function in normotensive, normoalbuminuric patients with type 2 diabetes. Objective: To evaluate the effect of prolonged ACE inhibition on renal function and albuminuria in patients with type 2 diabetes. Design: Randomized, double-blind, placebo-controlled trial with 6- year follow-up. Setting: Eight outpatient clinics coordinated by a department of medicine in a university hospital. Patients: 156 patients in whom type 2 diabetes was diagnosed after 40 years of age who had a baseline mean blood pressure less than 107 mm Hg and albuminuria (albumin excretion ≤30 mg/24 h). Intervention: Enalapril, 10 mg/d, or placebo. Measurements: Degree of albuminuria at 24 hours, creatinine clearance, blood pressure, and hemoglobin A(1c) values. Results: Enalapril therapy decreased albumin excretion from a mean ± SD of 11.6 ± 7 mg/24 h to 9.7 ± 6 mg/24 h at 2 years. This was followed by a gradual increase to 15.8 ± 8 mg/24 h at 6 years. In the placebo group, albumin excretion increased from 10.8 ± 8 mg/24 h to 26.5 ± 10 mg/24 h at 6 years (P = 0.001 for enalapril compared with placebo). Transition to microalbuminuria occurred in 15 of 79 (19%) placebo recipients and 5 of 77 (6.5%) enalapril recipients. Enalapril treatment resulted in an absolute risk reduction of 12.5% (95% Cl, 2% to 23%; P = 0.042) for development of microalbuminuria. After 6 years, creatinine clearance decreased from 1.78 ± 0.13 mL/s to 1.63 ± 0.12 ml/s (mean decrease, 0.025 mL/s per year) in enalapril recipients and from 1.81 ± 0.15 mL/s to 1.57 ± 0.17 mL/s (mean decrease, 0.04 mL/s per year) in placebo recipients (P = 0.040). Hemoglobin A(1c) values decreased modestly in both groups. Mean blood pressure remained normal (<107 mm Hg) in all patients. Conclusions: Enalapril attenuated the decline in renal function and reduced the extent of albuminuria in normotensive, normoalbuminuric patients with type 2 diabetes. Further research is needed to determine whether this treatment forestalls the development of overt nephropathy.

Original languageEnglish
Pages (from-to)982-988
Number of pages7
JournalAnnals of Internal Medicine
Volume128
Issue number12 PART 1
DOIs
StatePublished - 15 Jun 1998

Fingerprint

Dive into the research topics of 'Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial'. Together they form a unique fingerprint.

Cite this